Cargando…
988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018
BACKGROUND: Interim estimates of 2017–2018 influenza vaccine effectiveness (VE) against influenza A(H3N2)-related illness in the United States indicated better protection among young children than among older children and adolescents. We examined VE against influenza A(H3N2) illness during five A(H3...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254929/ http://dx.doi.org/10.1093/ofid/ofy210.825 |
_version_ | 1783373839567159296 |
---|---|
author | Flannery, Brendan L Chung, Jessie Jackson, Michael L Jackson, Lisa A Monto, Arnold S Martin, Emily T Belongia, Edward McLean, Huong Zimmerman, Richard K Nowalk, Mary Patricia Gaglani, Manjusha Griffin, Marie R Talbot, H Keipp Treanor, John J Spencer, Sarah Fry, Alicia M |
author_facet | Flannery, Brendan L Chung, Jessie Jackson, Michael L Jackson, Lisa A Monto, Arnold S Martin, Emily T Belongia, Edward McLean, Huong Zimmerman, Richard K Nowalk, Mary Patricia Gaglani, Manjusha Griffin, Marie R Talbot, H Keipp Treanor, John J Spencer, Sarah Fry, Alicia M |
author_sort | Flannery, Brendan L |
collection | PubMed |
description | BACKGROUND: Interim estimates of 2017–2018 influenza vaccine effectiveness (VE) against influenza A(H3N2)-related illness in the United States indicated better protection among young children than among older children and adolescents. We examined VE against influenza A(H3N2) illness during five A(H3N2)-predominant seasons from 2010–2011 through 2016–2017 to investigate differences between VE among younger vs. older children. METHODS: We analyzed data from 11,736 outpatients aged <18 years with medically attended acute respiratory illnesses enrolled at US Flu VE Network study sites during five influenza A(H3N2)-predominant seasons. Respiratory specimens from all enrollees were tested for influenza viruses using reverse transcription PCR. Children with documented receipt of the recommended number of doses of current season inactivated influenza vaccine at least 14 days before illness onset were considered fully vaccinated; partially vaccinated children and those who received live attenuated influenza vaccine were excluded. Vaccine effectiveness was estimated as 100 × (1 – adjusted odds ratio) from multivariable logistic regression adjusting for study site, age, sex, presence of high-risk medical conditions, and days from illness onset to enrollment comparing odds of vaccination among A(H3N2)-positive cases vs. influenza-negative controls. RESULTS: A total of 1,854 influenza A(H3N2) cases and 9,882 influenza-negative controls were included; 494 (28%) influenza A(H3N2) cases and 3,637 (41%) controls were fully vaccinated before illness onset. VE ranged from 26% (95% confidence interval [CI], −17% to 53%) to 60% (38%–75%) among children aged 6 months–4 years and from 9% (−16% to 29%) to 66% (37%–82%) among 5–17 year olds (figure). During 2012–2013 and 2014–2015, A(H3N2) VE estimates were significantly higher among younger compared with older children (P < 0.05); in other seasons before 2017–2018, A(H3N2) VE estimates were similar among younger and older children. CONCLUSION: Higher VE against A(H3N2) viruses in younger vs. older children in some seasons suggests immunologic differences in response to vaccine components. Overall, inactivated influenza vaccine provided moderate protection against A(H3N2)-related illness among children. DISCLOSURES: M. L. Jackson, sanofi pasteur: Grant Investigator, Research support. L. A. Jackson, Novartis: Grant Investigator, Research support. R. K. Zimmerman, sanofi pasteur: Grant Investigator, Research support. Pfizer: Grant Investigator, Research support. Merck: Grant Investigator, Research support. M. P. Nowalk, Merck: Grant Investigator, Research support. Pfizer: Grant Investigator, Research support. M. R. Griffin, MedImmune: Grant Investigator, Research support. H. K. Talbot, sanofi pasteur: Investigator, Research grant. Gilead: Investigator, Research grant. MedImmune: Investigator, Research grant. Vaxinnate: Safety Board, none. Seqirus: Safety Board, none. J. J. Treanor, Novartis: Board Member and Consultant, Consulting fee. |
format | Online Article Text |
id | pubmed-6254929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62549292018-11-28 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 Flannery, Brendan L Chung, Jessie Jackson, Michael L Jackson, Lisa A Monto, Arnold S Martin, Emily T Belongia, Edward McLean, Huong Zimmerman, Richard K Nowalk, Mary Patricia Gaglani, Manjusha Griffin, Marie R Talbot, H Keipp Treanor, John J Spencer, Sarah Fry, Alicia M Open Forum Infect Dis Abstracts BACKGROUND: Interim estimates of 2017–2018 influenza vaccine effectiveness (VE) against influenza A(H3N2)-related illness in the United States indicated better protection among young children than among older children and adolescents. We examined VE against influenza A(H3N2) illness during five A(H3N2)-predominant seasons from 2010–2011 through 2016–2017 to investigate differences between VE among younger vs. older children. METHODS: We analyzed data from 11,736 outpatients aged <18 years with medically attended acute respiratory illnesses enrolled at US Flu VE Network study sites during five influenza A(H3N2)-predominant seasons. Respiratory specimens from all enrollees were tested for influenza viruses using reverse transcription PCR. Children with documented receipt of the recommended number of doses of current season inactivated influenza vaccine at least 14 days before illness onset were considered fully vaccinated; partially vaccinated children and those who received live attenuated influenza vaccine were excluded. Vaccine effectiveness was estimated as 100 × (1 – adjusted odds ratio) from multivariable logistic regression adjusting for study site, age, sex, presence of high-risk medical conditions, and days from illness onset to enrollment comparing odds of vaccination among A(H3N2)-positive cases vs. influenza-negative controls. RESULTS: A total of 1,854 influenza A(H3N2) cases and 9,882 influenza-negative controls were included; 494 (28%) influenza A(H3N2) cases and 3,637 (41%) controls were fully vaccinated before illness onset. VE ranged from 26% (95% confidence interval [CI], −17% to 53%) to 60% (38%–75%) among children aged 6 months–4 years and from 9% (−16% to 29%) to 66% (37%–82%) among 5–17 year olds (figure). During 2012–2013 and 2014–2015, A(H3N2) VE estimates were significantly higher among younger compared with older children (P < 0.05); in other seasons before 2017–2018, A(H3N2) VE estimates were similar among younger and older children. CONCLUSION: Higher VE against A(H3N2) viruses in younger vs. older children in some seasons suggests immunologic differences in response to vaccine components. Overall, inactivated influenza vaccine provided moderate protection against A(H3N2)-related illness among children. DISCLOSURES: M. L. Jackson, sanofi pasteur: Grant Investigator, Research support. L. A. Jackson, Novartis: Grant Investigator, Research support. R. K. Zimmerman, sanofi pasteur: Grant Investigator, Research support. Pfizer: Grant Investigator, Research support. Merck: Grant Investigator, Research support. M. P. Nowalk, Merck: Grant Investigator, Research support. Pfizer: Grant Investigator, Research support. M. R. Griffin, MedImmune: Grant Investigator, Research support. H. K. Talbot, sanofi pasteur: Investigator, Research grant. Gilead: Investigator, Research grant. MedImmune: Investigator, Research grant. Vaxinnate: Safety Board, none. Seqirus: Safety Board, none. J. J. Treanor, Novartis: Board Member and Consultant, Consulting fee. Oxford University Press 2018-11-26 /pmc/articles/PMC6254929/ http://dx.doi.org/10.1093/ofid/ofy210.825 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Flannery, Brendan L Chung, Jessie Jackson, Michael L Jackson, Lisa A Monto, Arnold S Martin, Emily T Belongia, Edward McLean, Huong Zimmerman, Richard K Nowalk, Mary Patricia Gaglani, Manjusha Griffin, Marie R Talbot, H Keipp Treanor, John J Spencer, Sarah Fry, Alicia M 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title | 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title_full | 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title_fullStr | 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title_full_unstemmed | 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title_short | 988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018 |
title_sort | 988. effectiveness of seasonal influenza vaccines against influenza a(h3n2) illness among children aged <18 years, us flu ve network, 2010–2018 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254929/ http://dx.doi.org/10.1093/ofid/ofy210.825 |
work_keys_str_mv | AT flannerybrendanl 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT chungjessie 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT jacksonmichaell 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT jacksonlisaa 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT montoarnolds 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT martinemilyt 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT belongiaedward 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT mcleanhuong 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT zimmermanrichardk 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT nowalkmarypatricia 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT gaglanimanjusha 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT griffinmarier 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT talbothkeipp 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT treanorjohnj 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT spencersarah 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 AT fryaliciam 988effectivenessofseasonalinfluenzavaccinesagainstinfluenzaah3n2illnessamongchildrenaged18yearsusfluvenetwork20102018 |